Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Share-based Compensation (2023 - 2025)

Monte Rosa Therapeutics' Share-based Compensation history spans 3 years, with the latest figure at $4.3 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 3.58% year-over-year to $4.3 million; the TTM value through Dec 2025 reached $18.9 million, up 4.08%, while the annual FY2025 figure was $18.9 million, 4.08% up from the prior year.
  • Share-based Compensation reached $4.3 million in Q4 2025 per GLUE's latest filing, down from $4.4 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $5.3 million in Q1 2025 to a low of $4.0 million in Q1 2023.
  • Average Share-based Compensation over 3 years is $4.5 million, with a median of $4.4 million recorded in 2023.
  • The largest YoY upside for Share-based Compensation was 22.62% in 2024 against a maximum downside of 4.16% in 2024.
  • A 3-year view of Share-based Compensation shows it stood at $4.1 million in 2023, then grew by 9.7% to $4.5 million in 2024, then fell by 3.58% to $4.3 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Share-based Compensation are $4.3 million (Q4 2025), $4.4 million (Q3 2025), and $4.9 million (Q2 2025).